Comparison of the effects of alendronate and alfacalcidol on hip bone mineral density and bone turnover in Japanese men having osteoporosis or osteopenia with clinical risk factors for fractures

Yonsei Medical Journal

Volumn 50, Issue 4, 2009, Pages 474-481

  Iwamoto, Jun ^a   Sato, Yoshihiro ^b   Uzawa, Mitsuyoshi ^c   Takeda, Tsuyoshi ^a   Matsumoto, Hideo ^a  

^a KEIO UNIVERSITY   (Japan)

^b Mitate Hospital   (Japan)

^c Keiyu Orthopaedic Hospital   (Japan)

Author keywords

Alendronate; Alfacalcidol; Fracture risk; Men; Osteopenia; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; CALCIUM; PARATHYROID HORMONE; PHOSPHATE;

AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; EPIGASTRIC PAIN; FRACTURE; HIP; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; RISK FACTOR; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; ALENDRONATE; ASIAN CONTINENTAL ANCESTRY GROUP; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; FRACTURES, BONE; HIP JOINT; HUMANS; HYDROXYCHOLECALCIFEROLS; MALE; MIDDLE AGED; OSTEOPOROSIS; TREATMENT OUTCOME;

EID: 70449700123     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2009.50.4.474     Document Type: Article

References (36)

1. Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-1443
2. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348: 1535-1541
3. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998;280:2077-2082 (Pubitemid 29014065)
4. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350:1189-1199 (Pubitemid 38339363)
5. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Longterm Extension (FLEX): a randomized trial. JAMA 2006;296: 2927-2938 (Pubitemid 46021497)
6. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C; Osteoporsis Methodology Group and The Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-578
7. Papapoulos SE, Quandt SA, Liberman UA, Hochberg MC, Thompson DE. Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos Int 2005;16:468-474
8. Liberman UA, Hochberg MC, Geusens P, Shah A, Lin J, Chattopadhyay A, et al. Hip and non-spine fracture risk reductions differ among antiresorptive agents: Evidence from randomised controlled trials. Int J Clin Pract 2006;60:1394-1400 (Pubitemid 44560336)
9. Hochberg MC, Thompson DE, Black DM, Quandt SA, Cauley J, Geusens P, et al. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res 2005;20: 971-976 (Pubitemid 40712821)
10. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000;343:604-610
11. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK. The components of excess mortality after hip fracture. Bone 2003;32:468-473 (Pubitemid 39665705)
12. Tsuboi M, Hasegawa Y, Suzuki S, Wingstrand H, Thorngren KG. Mortality and mobility after hip fracture in Japan: a ten-year follow-up. J Bone Joint Surg Br 2007;89:461-466
13. Hasegawa Y, Suzuki S, Wingstrand H. Risk of mortality following hip fracture in Japan. J Orthop Sci 2007;12:113-117 (Pubitemid 46723674)
14. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 2002;87:1586-1592 (Pubitemid 34615244)
15. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, et al. Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res 2004;19:1250-1258 (Pubitemid 41094365)
16. Ringe JD, Orwoll E, Daifotis A, Lombardi A. Treatment of male osteoporosis: recent advances with alendronate. Osteoporos Int 2002;13:195-199 (Pubitemid 34408184)
17. Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 2006;26:427-431 (Pubitemid 43318323)
18. Ringe JD, Farahmand P, Schacht E, Rozehnal A. Superiority of a combined treatment of Alendronate and Alfacalcidol compared to the combination of Alendronate and plain vitamin D or Alfacalcidol alone in established postmenopausal or male osteoporosis (AAC-Trial). Rheumatol Int 2007;27:425-434 (Pubitemid 46294994)
19. Gonnelli S, Cepollaro C, Montagnani A, Bruni D, Caffarelli C, Breschi M, et al. Alendronate treatment in men with primary osteoporosis: a three-year longitudinal study. Calcif Tissue Int 2003;73:133-139 (Pubitemid 37082359)
20. Ringe JD, Dorst A, Faber H, Ibach K. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 2004;24:110-113 (Pubitemid 38388755)
21. Orimo H, Sugioka Y, Fukunaga M, Muto Y, Hotokebuchi T, Gorai I, et al. Diagnostic criteria of primary osteoporosis. J Bone Miner Metab 1998;16:139-150
22. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001;19:331-337
23. Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, et al. Assessment of fracture risk. Osteoporos Int 2005;16:581-589
24. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, et al. A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. The Alendronate Phase III Osteoporosis Treatment Research Group. Osteoporos Int 1999;10:183-192 (Pubitemid 29458712)
25. Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, Yamamoto K, et al. The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial. Curr Ther Res 2002;63:606-620
26. Orimo H, Shiraki M, Hayashi Y, Hoshino T, Onaya T, Miyazaki S, et al. Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994;54:370-376 (Pubitemid 24138753)
27. Nishizawa Y, Nakamura T, Ohta H, Kushida K, Gorai I, Shiraki M, et al. Guidelines for the use of biochemical markers of bone turnover in osteoporosis (2004). J Bone Miner Metab 2005; 23:97-104.
28. Seeman E. Unresolved issues in osteoporosis in men. Rev Endocr Metab Disord 2001;2:45-64.
29. Resch H, Pietschmann P, Woloszczuk W, Krexner E, Bernecker P, Willvonseder R. Bone mass and biochemical parameters of bone metabolism in men with spinal osteoporosis. Eur J Clin Invest 1992;22:542-545
30. Sharp CA, Worsfold M, Rowlands PR, Davie MWJ. Accurate prediction of spinal osteoporosis in men using a biochemical measure of collagen balance. Bone 1994;15:243.
31. Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, et al. Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res 2000;15: 770-779 (Pubitemid 30174031)
32. Schacht E. Rationale for treatment of involutional osteoporosis in women and for prevention and treatment of corticosteroidinduced osteoporosis with alfacalcidol. Calcif Tissue Int 1999;65: 317-327 (Pubitemid 29471014)
33. Shiraishi A, Higashi S, Masaki T, Saito M, Ito M, Ikeda S, et al. A comparison of alfacalcidol and menatetrenone for the treatment of bone loss in an ovariectomized rat model of osteoporosis. Calcif Tissue Int 2002;71:69-79. (Pubitemid 36934779)
34. Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, et al. Effect of Vitamin D on falls: a meta-analysis. JAMA 2004;291:1999-2006.
35. Jesudason D, Need AG, Horowitz M, O'Loughlin PD, Morris HA, Nordin BE. Relationship between serum 25-hydroxy vitamin D and bone resorption markers in vitamin D insufficiency. Bone 2002;31:626-630 (Pubitemid 35449707)
36. de Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006;355:675-684